Interview with the President and Chairman: Positron Corporation (POSC)
inShare
Joseph Oliverio, President and Chairman of the board, has been instrumental in guiding Positron Corporation’s cardiac PET technology and has provided the vision of their molecular imaging strategy. He practiced as a certified nuclear medicine technologist and has performed over 13,000 cardiac and/or oncology scans, imaged with Positron devices... More
TWST: Can you provide an overview of Positron and summarize its value proposition?
Mr. Oliverio: We are a nuclear medicine health care company that specializes in the businesses of positron emission tomography, specifically cardiac PET imaging. Cardiac PET in general is a superior method in diagnostic nuclear medicine for the detection of coronary artery disease, which is a major contributor to the leading cause of deaths in the United States. We are a pioneer in nuclear cardiology and have been for the past 30 years. We are currently establishing a unique position by vertically integrating the fragmented and limited supply environment that exists in the cardiac PET marketplace today.
We feel that our value proposition is that we aim to provide nuclear cardiologists with an end-to-end solution by offering award-winning imaging technology, clinical services, imaging agents and financing packages, all conveniently from a single source. We are trying to approach the market to stabilize and expand it. The cardiac PET supply chain will bring substantial advantages in accelerating the adoption of this superior modality and growth of the nuclear cardiology industry in general. Additionally, we see our Attrius system as a powerful tool for both Positron and our customers, as we can offer them a cost-effective solution to PET/CT.
TWST: You mentioned Attrius, which is the only FDA-approved PET scan optimized for cardiac imaging. What is its install base, and what does that number mean in terms of percentages of potential market in the U.S. and the world?
Mr. Oliverio: In 2010, we entered the market with the Attrius system and sold 13 systems in that year. In 2011, the cardiac PET market's explosive growth came to a h
News 
Market Data 
Discover 
AI
